BRPI0606187A2 - comprimidos com capacidade de dispersão da substáncia do fármaco melhorada - Google Patents

comprimidos com capacidade de dispersão da substáncia do fármaco melhorada

Info

Publication number
BRPI0606187A2
BRPI0606187A2 BRPI0606187-7A BRPI0606187A BRPI0606187A2 BR PI0606187 A2 BRPI0606187 A2 BR PI0606187A2 BR PI0606187 A BRPI0606187 A BR PI0606187A BR PI0606187 A2 BRPI0606187 A2 BR PI0606187A2
Authority
BR
Brazil
Prior art keywords
drug substance
tablets
improved drug
vehicle
dispersibility
Prior art date
Application number
BRPI0606187-7A
Other languages
English (en)
Inventor
Nathalie Bernigal
Eric Garcia
Susanne Page
Joseph Tardio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0606187(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0606187A2 publication Critical patent/BRPI0606187A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPRIMIDOS COM CAPACIDADE DE DISPERSãO DA SUBSTáNCIA DO FáRMACO MELHORADA. A presente invenção refere-se a um método para a preparação de composições farmacêuticas na forma de comprimidos com capacidade de dispersão da substância do fármaco melhorada, o referido método sendo caracterizado pelo fato de que ele compreende as etapas de: a) preparar uma dispersão de pelo menos uma substância de fármaco farmaceuticamente ativa e pelo menos um tensoativo e/ou ligante em um líquido; b) preparar um veículo pela aglutinação a seco de um ou mais excipiente(s) incluindo pelo menos um veículo poroso; e c) granular por pulverização a dispersão preparada sob a) por cima do veículo preparado sob b) com a finalidade de ser obtido um produto granulado por pulverização.
BRPI0606187-7A 2005-02-25 2006-02-16 comprimidos com capacidade de dispersão da substáncia do fármaco melhorada BRPI0606187A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101458 2005-02-25
PCT/EP2006/001395 WO2006089674A2 (en) 2005-02-25 2006-02-16 Tablets with improved drug substance dispersibility

Publications (1)

Publication Number Publication Date
BRPI0606187A2 true BRPI0606187A2 (pt) 2009-06-09

Family

ID=36406213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606187-7A BRPI0606187A2 (pt) 2005-02-25 2006-02-16 comprimidos com capacidade de dispersão da substáncia do fármaco melhorada

Country Status (20)

Country Link
US (2) US20060193910A1 (pt)
EP (2) EP1855655A2 (pt)
JP (1) JP2008531509A (pt)
KR (1) KR20070094666A (pt)
CN (1) CN101128189A (pt)
AR (1) AR055561A1 (pt)
AU (1) AU2006218193A1 (pt)
BR (1) BRPI0606187A2 (pt)
CA (1) CA2598762A1 (pt)
CR (1) CR9292A (pt)
IL (1) IL185011A0 (pt)
MA (1) MA29268B1 (pt)
MX (1) MX2007009571A (pt)
NO (1) NO20074092L (pt)
NZ (1) NZ560232A (pt)
RU (1) RU2007129642A (pt)
TW (1) TW200640502A (pt)
UA (1) UA90708C2 (pt)
WO (1) WO2006089674A2 (pt)
ZA (1) ZA200706495B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
SG185257A1 (en) * 2007-10-10 2012-11-29 Avantor Performance Mat Inc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
RU2537224C2 (ru) * 2009-01-23 2014-12-27 Ф.Хоффманн-Ля Рош Аг Фармацевтическая композиция, содержащая алеглитазар
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN102641302B (zh) * 2011-02-18 2016-01-20 上海张江中药现代制剂技术工程研究中心 一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) * 2011-05-04 2012-12-10 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения атеросклероза
CN104784239B (zh) * 2015-04-28 2017-12-26 新乡医学院第一附属医院 一种快速溶出的珍菊降压片及其制备工艺
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
WO2017003137A1 (ko) * 2015-06-30 2017-01-05 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
KR20190085046A (ko) * 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
CN109701441B (zh) * 2018-12-16 2021-04-09 桂林理工大学 一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) * 2020-04-27 2020-08-18 上海应用技术大学 一种通用型花肥速释片及其制备方法和应用
CN116602928A (zh) * 2023-06-30 2023-08-18 康普药业股份有限公司 一种甲苯磺酸艾多沙班组合物和制备方法
US12296050B2 (en) * 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions
CN119857081B (zh) * 2025-01-16 2025-10-17 江苏亚邦爱普森药业有限公司 一种乌帕替尼缓释片及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110880A (en) * 1991-01-30 1999-06-30 The Wellcome Foundation Ltd Water-dispersible tablets
DE69231395T3 (de) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
MX9702162A (es) 1994-09-22 1997-06-28 Akzo Nobel Nv Procedimiento para hacer unidades de dosis mediante granulacion en humedo.
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
DE69732492T2 (de) 1996-12-02 2006-03-30 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
CA2273810A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
GB9825242D0 (en) 1998-11-19 1999-01-13 Cambridge Advanced Tech Genetically modified plants with altered starch
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
KR100437587B1 (ko) 1999-02-24 2004-06-30 에프. 호프만-라 로슈 아게 3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
TR200102490T2 (tr) 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil türevleri
DE60014537T2 (de) 1999-03-06 2006-02-02 Roche Diagnostics Gmbh Dna polymerase aus i(pyrobaculum islandicum)
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
SI1103545T1 (en) 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
MXPA03000366A (es) 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
JP4116436B2 (ja) 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス（ｓｅｌｍ）
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
CA2444395C (en) 2001-04-23 2010-12-21 F. Hoffmann-La Roche Ag Use of nk-1 receptor antagonists against benign prostatic hyperplasia
CN1264847C (zh) 2001-05-14 2006-07-19 弗·哈夫曼-拉罗切有限公司 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
DK1501804T3 (da) 2002-04-26 2009-10-12 Hoffmann La Roche Isoquinolinderivat MAO-B-inhibitorer
EP1511718B1 (en) 2002-05-29 2009-05-06 F. Hoffmann-La Roche Ag N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
JP4384053B2 (ja) 2002-12-13 2009-12-16 エフ．ホフマン−ラ ロシュ アーゲー ３ｈ−キナゾリン−４−オン誘導体
NZ541243A (en) 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics

Also Published As

Publication number Publication date
NO20074092L (no) 2007-09-04
IL185011A0 (en) 2007-12-03
WO2006089674A2 (en) 2006-08-31
EP1855655A2 (en) 2007-11-21
NZ560232A (en) 2010-11-26
US20060193910A1 (en) 2006-08-31
AU2006218193A1 (en) 2006-08-31
MA29268B1 (fr) 2008-02-01
UA90708C2 (ru) 2010-05-25
CR9292A (es) 2010-04-21
JP2008531509A (ja) 2008-08-14
EP2281556A1 (en) 2011-02-09
RU2007129642A (ru) 2009-03-27
WO2006089674A3 (en) 2007-02-08
CN101128189A (zh) 2008-02-20
TW200640502A (en) 2006-12-01
ZA200706495B (en) 2008-10-29
KR20070094666A (ko) 2007-09-20
AR055561A1 (es) 2007-08-22
US20090304795A1 (en) 2009-12-10
MX2007009571A (es) 2007-09-21
CA2598762A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
BRPI0606187A2 (pt) comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
HRP20192064T1 (hr) Formulacije apiksabana
Agrawal et al. Hydrotropic solubilization of nimesulide for parenteral administration
Jain Solubilization of indomethacin using hydrotropes for aqueous injection
Spanakis et al. Controlled release of 5-fluorouracil from microporous zeolites
Sruti et al. Improvement in the dissolution rate and tableting properties of cefuroxime axetil by melt-granulated dispersion and surface adsorption
BRPI0608853A8 (pt) Composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
BR112013007457A8 (pt) Formulações farmacêuticas contendo rifaximina, processos para a sua obtenção e método de tratar doença intestinal
WO2006131481A1 (de) Herstellung von festen lösungen schwerlöslicher wirkstoffe durch kurzzeitüberhitzung und schnelle trocknung
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
WO2008049633A3 (en) Spray-freeze-drying process for the preparation of pellets comprising percolation drying
Pandit et al. In vitro-in vivo evaluation of fast-dissolving tablets containing solid dispersion of pioglitazone hydrochloride
AR066000A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de pramipexol
AR056471A1 (es) Formulaciones de acetato de bazedoxifeno
WO2014044342A1 (de) Magnesiumhydroxidcarbonat als trägermaterial in wirkstoffhaltigen zubereitungen
Manukonda et al. Solid dispersions-an approach to enhance the dissolution rate of Clopidogrel bisulphate
Mathavan et al. Morphological, stability, and hypoglycemic effects of new Gliclazide-bile acid microcapsules for Type 1 diabetes treatment: the microencapsulation of anti-diabetics using a microcapsule-stabilizing bile acid
WO2008030512A3 (en) Polystyrene sulfonate polymer tablets, their preparation and use
CN103083345A (zh) 一种宠物用广谱抗寄生虫病的复方伊维菌素片剂
JPWO2017170763A1 (ja) 崩壊錠及びその製造方法
He et al. Freeze-drying of silymarin-loaded solid lipid nanoparticles (SM-SLN)
CN105534980A (zh) 瑞格列奈盐酸二甲双胍的药物组合物及其制剂工艺
Srikanth et al. Dissolution rate enhancement of bicalutamide by adsorption process

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013.